

Joint Event

# 4<sup>th</sup> EUROPEAN BIOPHARMA CONGRESS

&

# 6<sup>th</sup> International Conference and Exhibition on PHARMACOLOGY AND ETHNOPHARMACOLOGY

November 09-11, 2017 Vienna, Austria

## **Selenium and its compounds as prospective drugs in oncology**

**Melnik Milan**

Faculty of Medicine Comenius University in Bratislava, Slovakia

In last years, there have been some notable developments as several areas of inorganic pharmaceutical that have potentially for – reacting importance for future medicinal applications and research. One of the highly significant developments in the field of oncology and hematology is the application role selenium compounds. Selenium ions play an important role in biological systems, and without their catalytic presence intracellular or ultratrace amounts many essential co – factors for many biochemical reactions would endogenous antioxidant enzymes. Selenium is an essential component of several endogenous antioxidant enzymes. Selenium affects the transcription of multiple defense and repair genes to protect against metal – induced pathologies. Selenium creates stable complexes a wide variety of organic molecules that can provide required biological affinity and therapeutic activity veritable for targeting specific locations in the body. The aim of this review is a critical evaluation of selenium complexes used for therapy or diagnosis of various diseases in oncology.